Literature DB >> 8964839

Serum immunoreactive activin A levels in normal subjects and patients with various diseases.

K Harada1, Y Shintani, Y Sakamoto, M Wakatsuki, K Shitsukawa, S Saito.   

Abstract

We developed and validated a RIA for measuring serum activin A. The least detectable value of this assay was 0.1 micrograms/L, and the antibody used cross-reacted slightly with bovine inhibin (3.2%) and porcine activin AB (10.0%) but not with porcine activin B (< 0.5%). Serum activin A was extracted with acetonitrile and trifluoroacetic acid to get rid of the interaction with possible binding proteins in serum. As a result of this extraction procedure, the dose-response curve of serum extract was parallel to the standard curve and a single immunoreactive (ir-) peak was demonstrated on gel chromatographic analysis with constant recovery rates over 80%. Serum ir-activin A level in healthy adults was 1.27 +/- 0.03 micrograms/L (mean +/- SEM, n = 180); being 1.38 +/- 0.05 micrograms/L (n = 90) in male, and 1.16 +/- 0.05 micrograms/L (n = 90) in female subjects, with a tendency to increase with age. Serum ir-activin A level during pregnancy showed a marked increase with the advance of gestation; 1.65 +/- 0.41 micrograms/L (n = 7) in the early, 4.50 +/- 1.13 micrograms/L (n = 21) in the middle, and 16.32 +/- 2.25 micrograms/L (n = 26) in the late trimester, with a rapid decline after delivery. On the other hand, serum ir-activin A level was elevated in patients with hyperthyroidism (1.91 +/- 0.37 micrograms/L, n = 31), liver cirrhosis (2.03 +/- 0.71 micrograms/L, n = 10), chronic renal failure (3.41 +/- 0.34 micrograms/L, n = 41), and advanced solid cancer (2.24 +/- 0.52 micrograms/L, n = 67). These findings indicate that serum ir-activin A level varies with physiological conditions such as aging and pregnancy, and that it may reflect the altered production and metabolism of activin A in certain diseased conditions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8964839     DOI: 10.1210/jcem.81.6.8964839

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

1.  In vitro release of activin A from human normal and pathological thyroid tissues.

Authors:  P S Morpurgo; A Corsi; S Corbetta; L Vicentini; A Spada
Journal:  J Endocrinol Invest       Date:  2001-09       Impact factor: 4.256

2.  Reversible increase of serum activin A levels in women with Graves' disease.

Authors:  M Centanni; N Viceconti; S Luisi; F M Reis; L Gargano; F Maiani; A Franchi; G Canettieri; F Petraglia
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

3.  Loss of BMPR2 leads to high bone mass due to increased osteoblast activity.

Authors:  Jonathan W Lowery; Giuseppe Intini; Laura Gamer; Sutada Lotinun; Valerie S Salazar; Satoshi Ote; Karen Cox; Roland Baron; Vicki Rosen
Journal:  J Cell Sci       Date:  2015-02-06       Impact factor: 5.285

4.  Transforming Growth Factor-β Family Ligands Can Function as Antagonists by Competing for Type II Receptor Binding.

Authors:  Senem Aykul; Erik Martinez-Hackert
Journal:  J Biol Chem       Date:  2016-03-09       Impact factor: 5.157

5.  Virtual High-Throughput Screening To Identify Novel Activin Antagonists.

Authors:  Jie Zhu; Rama K Mishra; Gary E Schiltz; Yogeshwar Makanji; Karl A Scheidt; Andrew P Mazar; Teresa K Woodruff
Journal:  J Med Chem       Date:  2015-07-07       Impact factor: 7.446

Review 6.  Beyond TGFβ: roles of other TGFβ superfamily members in cancer.

Authors:  Lalage M Wakefield; Caroline S Hill
Journal:  Nat Rev Cancer       Date:  2013-05       Impact factor: 60.716

7.  Stress signaling from human mammary epithelial cells contributes to phenotypes of mammographic density.

Authors:  Rosa Anna DeFilippis; Colleen Fordyce; Kelley Patten; Hang Chang; Jianxin Zhao; Gerald V Fontenay; Karla Kerlikowske; Bahram Parvin; Thea D Tlsty
Journal:  Cancer Res       Date:  2014-08-29       Impact factor: 12.701

8.  New Ligand Binding Function of Human Cerberus and Role of Proteolytic Processing in Regulating Ligand-Receptor Interactions and Antagonist Activity.

Authors:  Senem Aykul; Erik Martinez-Hackert
Journal:  J Mol Biol       Date:  2016-01-21       Impact factor: 5.469

9.  Activin receptor signaling regulates prostatic epithelial cell adhesion and viability.

Authors:  Derek P Simon; Sivan Vadakkadath Meethal; Andrea C Wilson; Miguel J Gallego; Stephanie L Weinecke; Erin Bruce; Patrick F Lyons; Ryan J Haasl; Richard L Bowen; Craig S Atwood
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

10.  Activin A levels are associated with abnormal glucose regulation in patients with myocardial infarction: potential counteracting effects of activin A on inflammation.

Authors:  Geir Ø Andersen; Thor Ueland; Eva C Knudsen; Hanne Scholz; Arne Yndestad; Afaf Sahraoui; Camilla Smith; Tove Lekva; Kari Otterdal; Bente Halvorsen; Ingebjørg Seljeflot; Pål Aukrust
Journal:  Diabetes       Date:  2011-04-04       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.